EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Regulatory news and changes

Does patient-specific prescribing—or adding B12—make compounding permissible?

Dose Diligence research deskSection 04 · Page 5 of 17Last updated 17 Nov 2026

Neither is an automatic exemption. Section 503A recognises a change made for an identified patient that produces a significant difference for that patient, as determined by the prescribing practitioner. The prescription is one component of the analysis, not a substitute for the other statutory conditions. Section 503A. (uscode.house.gov)

FDA’s April 1, 2026 reminder specifically explains that a semaglutide-plus-B12 preparation may still be considered a copy, depending on the relevant ingredients, strengths and route. Do not turn the presence of an additive into a procurement qualification. FDA GLP-1 policy. (fda.gov)

FDA’s existing guidance also says that a patient name and formulation alone do not establish the required determination, and a lower price is not a sufficient formulation-related significant difference. Its four-or-fewer-prescriptions-per-calendar-month enforcement policy concerns the compounder and relevant product—not a scalable allowance for each clinic prescriber. FDA copy guidance. (fda.gov)

What did the September 2026 Empower warning letter add?

It provides a concrete example of FDA examining whether personalisation documentation is substantive. FDA identified records without prescriber determinations and records containing repeated, apparently pre-generated determinations. It also questioned whether formulation differences were pretextual in light of production volumes. These are FDA’s findings and concerns in a warning letter, not a court judgment or a finding about every facility under the same brand. September 18 warning letter. (fda.gov)

Recommended clinical/legal audit:

  • Sample how the actual prescriber reaches and records the patient-specific determination.
  • Identify supplier-written default reasons, mandatory dropdowns and copied language.
  • Confirm that the pharmacy receives and retains the relevant determination.
  • Separate genuine clinical decision-making from price-driven product routing.
  • Request the supplier’s response to relevant enforcement correspondence and evidence of subsequent resolution; do not assume either resolution or continuing noncompliance from an old letter alone.

Sources cited on this page

  1. uscode.house.gov · Source 1 ↗https://uscode.house.gov/us/usc/119-120/t21/s353a/
  2. uscode.house.gov · Source 2 ↗https://uscode.house.gov/us/usc/119-120/t21/s353a/?utm_source=openai
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  4. fda.gov · Source 4 ↗https://www.fda.gov/media/98973/download
  5. fda.gov · Source 5 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
  6. fda.gov · Source 6 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026?utm_source=openai
Section sources →